Trial · NCT02170519
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Oxygen Saturation (SpO2) From Baseline | 30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours | Readings were taken from the medical record and the data may not have been present at the exact time frames. |
| Primary | Percent Change in Oxygen Saturation (SpO2) From Baseline | dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour) | |
| Primary | Change in Mean Heart Rate From Baseline | 30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours | |
| Primary | Change in Mean Heart Rate From Baseline | dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour) | |
| Primary | Number of Treatment Failures | as long as subject was on drug up to approximately 24 hours | Treatment failure is defined as Central venous pressure (CVP) ≥ 20 mm Hg and any one of the following: 1. Cardiac Index (CI) \>/= 1.8 L/min/m2 2. Administration of \>/=0.1 ug/kg/min Epinephrine or Norepinephrine 3. MAP \</= 50 mmHg (or as appropriate for age in pediatrics). 4. SvO2\</= 55% (or \< 45% for patients with R to L intracardiac shunting and, thus, cyanosis at baseline.} |
| Primary | Change in Mean Pulmonary Artery Pressure (mPAP) From Baseline | 30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours | |
| Primary | Change in Mean Pulmonary Artery Pressure (mPAP) From Baseline | dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour) | |
| Secondary | Change in Cardiac Output (CO) From Baseline | 30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours | |
| Secondary | Change in Cardiac Output (CO) From Baseline | dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour) | |
| Secondary | Change in Mean Venous Oxygen Saturation (SvO2) From Baseline | 30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours | SvO2 represents an average of all the venous oxygen saturations of the various organs and tissues. |
| Secondary | Change in Mean Venous Oxygen Saturation (SvO2) From Baseline | dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02170519/registered